Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2020
SIETES contiene 93096 citas

 
 
 1 a 20 de 59 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KAA, Eikelboom JW. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010;363:1704-14. [Ref.ID 89554]
3.Tiene citas relacionadas Cita con resumen
Guyatt G, Hirsh J. Methodologists are not qualified to write clinical guidelines. Authors' reply. Lancet 2009;374:1327. [Ref.ID 86945]
4.Tiene citas relacionadas Cita con resumen
Eikelboom JW, Ginsberg JS, Hirsh J. Anticoagulation for venous thromboembolism. BMJ 2007;334:645. [Ref.ID 79696]
5.Tiene citas relacionadas Cita con resumen
Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M, for the Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006;296:935-42. [Ref.ID 77931]
6.Tiene citas relacionadas
Bhatt DL, Hirsh J. The (variable) definition of benefit in the case of clopidogrel vs aspirin. In reply. Arch Intern Med 2005;165:1310-1. [Ref.ID 74483]
8.
Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia. A critical review. Arch Intern Med 2004;164:361-9. [Ref.ID 69203]
9.
Warkentin TE, Roberts R S, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163:2518-24. [Ref.ID 68084]
10.
Crowter MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;121:1133-8. [Ref.ID 67398]
12.
Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003;138:720-3. [Ref.ID 66237]
13.
Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin?. Arch Intern Med 2002;162:2605-9. [Ref.ID 64396]
14.
Ginsberg JS, Hirsh J, Julian J, LaandeVries MV, Magier D, MacKinnon B, Gent M. Prevention and treatment of postphlebitic syndrome. Results of a 3-part study. Arch Intern Med 2001;161:2105-9. [Ref.ID 58626]
15.Tiene citas relacionadas Cita con resumen
Hirsh J, O'Donnell MJ. Venous thromboembolism after long flights: are airlines to blame?. Lancet 2001;357:1461-2. [Ref.ID 56491]
16. Cita con resumen
Hirsh J, Bates SM. Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective. Ann Intern Med 2001;134:409-17. [Ref.ID 55576]
17.Tiene citas relacionadas
Crowther M, Gent M, Ginsberg J, Hirsh J. Vitamin K in anticoagulation therapy. Authors' reply. Lancet 2001;357:638. [Ref.ID 55352]
18. Cita con resumen
Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Brurrows R, Kearon C, Geerts W, Kovacs M, Weitz JI, Robinson S, Whittom R, Couture G, for the Recurrence of Clot in This Pregnancy Study Group. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000;343:1439-44. [Ref.ID 53963]
19. Cita con resumen
20. Cita con resumen
Crowther MA, Julian J, McCarty D, Douketis J, Kovacs M, Biagoni L, Schnurr T, McGinnis J, Gent M, Hirsh J, Ginsberg J. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000;356:1551-3. [Ref.ID 53544]
Seleccionar todas
 
 1 a 20 de 59 siguiente >>